Report Detail
Global Killer-cell immunoglobulin-like receptors (KIRs) Market 2026 by Company, Regions, Type and Application, Forecast to 2032
- RnM4710094 |
- 17 June, 2026 |
- Global |
- 197 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Killer-cell immunoglobulin-like receptors (KIRs) market size was valued at US$ 88.49 million in 2025 and is forecast to a readjusted size of US$ 157 million by 2032 with a CAGR of 8.4% during review period.
Killer-cell immunoglobulin-like receptors (KIRs) are a family of transmembrane glycoprotein receptors mainly expressed on natural killer cells and subsets of T cells, and the term also refers to the related commercial products and services built around KIR proteins, KIR genes, ligand recognition, and functional immune analysis. They are not visible stand-alone devices, but molecular receptors located on the cell membrane, typically composed of extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail. Structurally, KIRs can contain two or three extracellular immunoglobulin-like domains, while functionally they include inhibitory and activating receptor types. Commercial products include genotyping kits, sequencing and testing services, flow cytometry antibodies, conjugated antibodies, recombinant proteins, plasmids, cell models, and reference antibodies for drug discovery. Their mechanism is based on recognizing human leukocyte antigen-related ligands and regulating natural killer cell cytotoxicity, immune tolerance, and immune surveillance. Major use scenarios include transplant immunogenetics, natural killer cell research, oncology immunology, immune phenotyping, therapeutic antibody discovery, cell therapy development, and reproductive immunology research.
Market growth opportunities are mainly supported by three demand streams. First, transplant immunogenetics and cell therapy are increasing the need to understand donor-recipient immune background, which supports demand for genotyping, receptor-ligand analysis, and immune risk assessment. Second, the rising importance of natural killer cells in oncology, infectious disease, and autoimmune research is expanding demand for flow cytometry antibodies, recombinant proteins, and functional validation materials. Third, more specific receptor targets are moving part of the market closer to translational development, especially in therapeutic antibody programs, immune monitoring, and potential companion testing workflows.
The main market challenges are clinical evidence, standardization, and commercial scale. These products are used mostly by specialized laboratories, transplant centers, academic institutes, and drug developers, so the customer base is much narrower than that of routine clinical diagnostics. Complex polymorphism, haplotype variation, gene copy number differences, and platform-specific interpretation create technical barriers in quality control and reporting. The value of routine KIR-based decision-making still requires stronger prospective evidence, so near-term market development should be assessed as steady professional adoption rather than mass-market expansion.
Downstream demand is expected to shift from single-product purchasing toward integrated solutions. Transplant-related users will increasingly combine genotyping, ligand matching, and long-term outcome data. Oncology immunology users will focus more on receptor expression, immune-cell functional status, and treatment response monitoring. Drug developers will require higher target specificity, antibody affinity validation, cytotoxicity mechanism studies, and clinical sample-based evidence. Faster-growing product categories are likely to include high-throughput typing, conjugated antibody panels, recombinant proteins, reference antibodies, and testing services designed for clinical research.
This report is a detailed and comprehensive analysis for global Killer-cell immunoglobulin-like receptors (KIRs) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Killer-cell immunoglobulin-like receptors (KIRs) market size and forecasts, in consumption value ($ Million), 2021-2032
Global Killer-cell immunoglobulin-like receptors (KIRs) market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Killer-cell immunoglobulin-like receptors (KIRs) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Killer-cell immunoglobulin-like receptors (KIRs) market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Killer-cell immunoglobulin-like receptors (KIRs)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Killer-cell immunoglobulin-like receptors (KIRs) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher Scientific, Becton Dickinson, Beckman Coulter Life Sciences, Bio-Rad, Revvity, Bio-Techne, Miltenyi Biotec, Merck, Abcam, Werfen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Killer-cell immunoglobulin-like receptors (KIRs) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
KIR Genotyping Products and Services
KIR/CD158 Antibodies and Flow Cytometry Reagents
Recombinant KIR Proteins and Related Research Reagents
Market segment by Target Structure
2D KIR Products
3D KIR Products
Pan-KIR or Mixed KIR Panel Products
Market segment by Function
Inhibitory KIR-related Products
Activating KIR-related Products
Mixed KIR Panel Products
Market segment by Application
Medical Science
Experiment
Other
Market segment by players, this report covers
Thermo Fisher Scientific
Becton Dickinson
Beckman Coulter Life Sciences
Bio-Rad
Revvity
Bio-Techne
Miltenyi Biotec
Merck
Abcam
Werfen
CareDx
GenDx
HistoGenetics
DKMS Life Science Lab
Scisco Genetics
Labcorp
GeneTex
Proteintech
Cell Signaling Technology
OriGene
MyBioSource
Aviva Systems Biology
NSJ Bioreagents
Boster Bio
KACTUS
ProteoGenix
Biorbyt
Abbexa
St John’s Laboratory
Innate Pharma
ACROBiosystems
Sino Biological
GenScript
CUSABIO
Solarbio
WeHelp
CapitalBio
Genomeditech
Abnova
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Killer-cell immunoglobulin-like receptors (KIRs) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Killer-cell immunoglobulin-like receptors (KIRs), with revenue, gross margin, and global market share of Killer-cell immunoglobulin-like receptors (KIRs) from 2021 to 2026.
Chapter 3, the Killer-cell immunoglobulin-like receptors (KIRs) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Killer-cell immunoglobulin-like receptors (KIRs) market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Killer-cell immunoglobulin-like receptors (KIRs).
Chapter 13, to describe Killer-cell immunoglobulin-like receptors (KIRs) research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Killer-cell immunoglobulin-like receptors (KIRs) by Type
- 1.3.1 Overview: Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value Market Share by Type in 2025
- 1.3.3 KIR Genotyping Products and Services
- 1.3.4 KIR/CD158 Antibodies and Flow Cytometry Reagents
- 1.3.5 Recombinant KIR Proteins and Related Research Reagents
- 1.4 Classification of Killer-cell immunoglobulin-like receptors (KIRs) by Target Structure
- 1.4.1 Overview: Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Target Structure: 2021 Versus 2025 Versus 2032
- 1.4.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value Market Share by Target Structure in 2025
- 1.4.3 2D KIR Products
- 1.4.4 3D KIR Products
- 1.4.5 Pan-KIR or Mixed KIR Panel Products
- 1.5 Classification of Killer-cell immunoglobulin-like receptors (KIRs) by Function
- 1.5.1 Overview: Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Function: 2021 Versus 2025 Versus 2032
- 1.5.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value Market Share by Function in 2025
- 1.5.3 Inhibitory KIR-related Products
- 1.5.4 Activating KIR-related Products
- 1.5.5 Mixed KIR Panel Products
- 1.6 Global Killer-cell immunoglobulin-like receptors (KIRs) Market by Application
- 1.6.1 Overview: Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Medical Science
- 1.6.3 Experiment
- 1.6.4 Other
- 1.7 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size & Forecast
- 1.8 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast by Region
- 1.8.1 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Region: 2021 VS 2025 VS 2032
- 1.8.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Region, (2021-2032)
- 1.8.3 North America Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Prospect (2021-2032)
- 1.8.4 Europe Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Prospect (2021-2032)
- 1.8.5 Asia-Pacific Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Prospect (2021-2032)
- 1.8.6 South America Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Prospect (2021-2032)
- 1.8.7 Middle East & Africa Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Prospect (2021-2032)
2 Company Profiles
- 2.1 Thermo Fisher Scientific
- 2.1.1 Thermo Fisher Scientific Details
- 2.1.2 Thermo Fisher Scientific Major Business
- 2.1.3 Thermo Fisher Scientific Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.1.4 Thermo Fisher Scientific Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Thermo Fisher Scientific Recent Developments and Future Plans
- 2.2 Becton Dickinson
- 2.2.1 Becton Dickinson Details
- 2.2.2 Becton Dickinson Major Business
- 2.2.3 Becton Dickinson Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.2.4 Becton Dickinson Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Becton Dickinson Recent Developments and Future Plans
- 2.3 Beckman Coulter Life Sciences
- 2.3.1 Beckman Coulter Life Sciences Details
- 2.3.2 Beckman Coulter Life Sciences Major Business
- 2.3.3 Beckman Coulter Life Sciences Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.3.4 Beckman Coulter Life Sciences Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Beckman Coulter Life Sciences Recent Developments and Future Plans
- 2.4 Bio-Rad
- 2.4.1 Bio-Rad Details
- 2.4.2 Bio-Rad Major Business
- 2.4.3 Bio-Rad Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.4.4 Bio-Rad Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Bio-Rad Recent Developments and Future Plans
- 2.5 Revvity
- 2.5.1 Revvity Details
- 2.5.2 Revvity Major Business
- 2.5.3 Revvity Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.5.4 Revvity Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Revvity Recent Developments and Future Plans
- 2.6 Bio-Techne
- 2.6.1 Bio-Techne Details
- 2.6.2 Bio-Techne Major Business
- 2.6.3 Bio-Techne Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.6.4 Bio-Techne Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Bio-Techne Recent Developments and Future Plans
- 2.7 Miltenyi Biotec
- 2.7.1 Miltenyi Biotec Details
- 2.7.2 Miltenyi Biotec Major Business
- 2.7.3 Miltenyi Biotec Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.7.4 Miltenyi Biotec Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Miltenyi Biotec Recent Developments and Future Plans
- 2.8 Merck
- 2.8.1 Merck Details
- 2.8.2 Merck Major Business
- 2.8.3 Merck Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.8.4 Merck Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Merck Recent Developments and Future Plans
- 2.9 Abcam
- 2.9.1 Abcam Details
- 2.9.2 Abcam Major Business
- 2.9.3 Abcam Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.9.4 Abcam Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Abcam Recent Developments and Future Plans
- 2.10 Werfen
- 2.10.1 Werfen Details
- 2.10.2 Werfen Major Business
- 2.10.3 Werfen Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.10.4 Werfen Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Werfen Recent Developments and Future Plans
- 2.11 CareDx
- 2.11.1 CareDx Details
- 2.11.2 CareDx Major Business
- 2.11.3 CareDx Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.11.4 CareDx Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 CareDx Recent Developments and Future Plans
- 2.12 GenDx
- 2.12.1 GenDx Details
- 2.12.2 GenDx Major Business
- 2.12.3 GenDx Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.12.4 GenDx Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 GenDx Recent Developments and Future Plans
- 2.13 HistoGenetics
- 2.13.1 HistoGenetics Details
- 2.13.2 HistoGenetics Major Business
- 2.13.3 HistoGenetics Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.13.4 HistoGenetics Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 HistoGenetics Recent Developments and Future Plans
- 2.14 DKMS Life Science Lab
- 2.14.1 DKMS Life Science Lab Details
- 2.14.2 DKMS Life Science Lab Major Business
- 2.14.3 DKMS Life Science Lab Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.14.4 DKMS Life Science Lab Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 DKMS Life Science Lab Recent Developments and Future Plans
- 2.15 Scisco Genetics
- 2.15.1 Scisco Genetics Details
- 2.15.2 Scisco Genetics Major Business
- 2.15.3 Scisco Genetics Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.15.4 Scisco Genetics Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.15.5 Scisco Genetics Recent Developments and Future Plans
- 2.16 Labcorp
- 2.16.1 Labcorp Details
- 2.16.2 Labcorp Major Business
- 2.16.3 Labcorp Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.16.4 Labcorp Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.16.5 Labcorp Recent Developments and Future Plans
- 2.17 GeneTex
- 2.17.1 GeneTex Details
- 2.17.2 GeneTex Major Business
- 2.17.3 GeneTex Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.17.4 GeneTex Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.17.5 GeneTex Recent Developments and Future Plans
- 2.18 Proteintech
- 2.18.1 Proteintech Details
- 2.18.2 Proteintech Major Business
- 2.18.3 Proteintech Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.18.4 Proteintech Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.18.5 Proteintech Recent Developments and Future Plans
- 2.19 Cell Signaling Technology
- 2.19.1 Cell Signaling Technology Details
- 2.19.2 Cell Signaling Technology Major Business
- 2.19.3 Cell Signaling Technology Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.19.4 Cell Signaling Technology Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.19.5 Cell Signaling Technology Recent Developments and Future Plans
- 2.20 OriGene
- 2.20.1 OriGene Details
- 2.20.2 OriGene Major Business
- 2.20.3 OriGene Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.20.4 OriGene Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.20.5 OriGene Recent Developments and Future Plans
- 2.21 MyBioSource
- 2.21.1 MyBioSource Details
- 2.21.2 MyBioSource Major Business
- 2.21.3 MyBioSource Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.21.4 MyBioSource Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.21.5 MyBioSource Recent Developments and Future Plans
- 2.22 Aviva Systems Biology
- 2.22.1 Aviva Systems Biology Details
- 2.22.2 Aviva Systems Biology Major Business
- 2.22.3 Aviva Systems Biology Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.22.4 Aviva Systems Biology Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.22.5 Aviva Systems Biology Recent Developments and Future Plans
- 2.23 NSJ Bioreagents
- 2.23.1 NSJ Bioreagents Details
- 2.23.2 NSJ Bioreagents Major Business
- 2.23.3 NSJ Bioreagents Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.23.4 NSJ Bioreagents Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.23.5 NSJ Bioreagents Recent Developments and Future Plans
- 2.24 Boster Bio
- 2.24.1 Boster Bio Details
- 2.24.2 Boster Bio Major Business
- 2.24.3 Boster Bio Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.24.4 Boster Bio Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.24.5 Boster Bio Recent Developments and Future Plans
- 2.25 KACTUS
- 2.25.1 KACTUS Details
- 2.25.2 KACTUS Major Business
- 2.25.3 KACTUS Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.25.4 KACTUS Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.25.5 KACTUS Recent Developments and Future Plans
- 2.26 ProteoGenix
- 2.26.1 ProteoGenix Details
- 2.26.2 ProteoGenix Major Business
- 2.26.3 ProteoGenix Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.26.4 ProteoGenix Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.26.5 ProteoGenix Recent Developments and Future Plans
- 2.27 Biorbyt
- 2.27.1 Biorbyt Details
- 2.27.2 Biorbyt Major Business
- 2.27.3 Biorbyt Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.27.4 Biorbyt Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.27.5 Biorbyt Recent Developments and Future Plans
- 2.28 Abbexa
- 2.28.1 Abbexa Details
- 2.28.2 Abbexa Major Business
- 2.28.3 Abbexa Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.28.4 Abbexa Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.28.5 Abbexa Recent Developments and Future Plans
- 2.29 St John’s Laboratory
- 2.29.1 St John’s Laboratory Details
- 2.29.2 St John’s Laboratory Major Business
- 2.29.3 St John’s Laboratory Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.29.4 St John’s Laboratory Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.29.5 St John’s Laboratory Recent Developments and Future Plans
- 2.30 Innate Pharma
- 2.30.1 Innate Pharma Details
- 2.30.2 Innate Pharma Major Business
- 2.30.3 Innate Pharma Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.30.4 Innate Pharma Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.30.5 Innate Pharma Recent Developments and Future Plans
- 2.31 ACROBiosystems
- 2.31.1 ACROBiosystems Details
- 2.31.2 ACROBiosystems Major Business
- 2.31.3 ACROBiosystems Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.31.4 ACROBiosystems Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.31.5 ACROBiosystems Recent Developments and Future Plans
- 2.32 Sino Biological
- 2.32.1 Sino Biological Details
- 2.32.2 Sino Biological Major Business
- 2.32.3 Sino Biological Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.32.4 Sino Biological Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.32.5 Sino Biological Recent Developments and Future Plans
- 2.33 GenScript
- 2.33.1 GenScript Details
- 2.33.2 GenScript Major Business
- 2.33.3 GenScript Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.33.4 GenScript Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.33.5 GenScript Recent Developments and Future Plans
- 2.34 CUSABIO
- 2.34.1 CUSABIO Details
- 2.34.2 CUSABIO Major Business
- 2.34.3 CUSABIO Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.34.4 CUSABIO Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.34.5 CUSABIO Recent Developments and Future Plans
- 2.35 Solarbio
- 2.35.1 Solarbio Details
- 2.35.2 Solarbio Major Business
- 2.35.3 Solarbio Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.35.4 Solarbio Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.35.5 Solarbio Recent Developments and Future Plans
- 2.36 WeHelp
- 2.36.1 WeHelp Details
- 2.36.2 WeHelp Major Business
- 2.36.3 WeHelp Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.36.4 WeHelp Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.36.5 WeHelp Recent Developments and Future Plans
- 2.37 CapitalBio
- 2.37.1 CapitalBio Details
- 2.37.2 CapitalBio Major Business
- 2.37.3 CapitalBio Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.37.4 CapitalBio Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.37.5 CapitalBio Recent Developments and Future Plans
- 2.38 Genomeditech
- 2.38.1 Genomeditech Details
- 2.38.2 Genomeditech Major Business
- 2.38.3 Genomeditech Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.38.4 Genomeditech Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.38.5 Genomeditech Recent Developments and Future Plans
- 2.39 Abnova
- 2.39.1 Abnova Details
- 2.39.2 Abnova Major Business
- 2.39.3 Abnova Killer-cell immunoglobulin-like receptors (KIRs) Product and Solutions
- 2.39.4 Abnova Killer-cell immunoglobulin-like receptors (KIRs) Revenue, Gross Margin and Market Share (2021-2026)
- 2.39.5 Abnova Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Killer-cell immunoglobulin-like receptors (KIRs) Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Killer-cell immunoglobulin-like receptors (KIRs) by Company Revenue
- 3.2.2 Top 3 Killer-cell immunoglobulin-like receptors (KIRs) Players Market Share in 2025
- 3.2.3 Top 6 Killer-cell immunoglobulin-like receptors (KIRs) Players Market Share in 2025
- 3.3 Killer-cell immunoglobulin-like receptors (KIRs) Market: Overall Company Footprint Analysis
- 3.3.1 Killer-cell immunoglobulin-like receptors (KIRs) Market: Region Footprint
- 3.3.2 Killer-cell immunoglobulin-like receptors (KIRs) Market: Company Product Type Footprint
- 3.3.3 Killer-cell immunoglobulin-like receptors (KIRs) Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
- 5.1 Global Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Killer-cell immunoglobulin-like receptors (KIRs) Market Forecast by Application (2027-2032)
6 North America
- 6.1 North America Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Type (2021-2032)
- 6.2 North America Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Application (2021-2032)
- 6.3 North America Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Country
- 6.3.1 North America Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Country (2021-2032)
- 6.3.2 United States Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 6.3.3 Canada Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
7 Europe
- 7.1 Europe Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Type (2021-2032)
- 7.2 Europe Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Application (2021-2032)
- 7.3 Europe Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Country
- 7.3.1 Europe Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Country (2021-2032)
- 7.3.2 Germany Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 7.3.3 France Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 7.3.5 Russia Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 7.3.6 Italy Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
8 Asia-Pacific
- 8.1 Asia-Pacific Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Region
- 8.3.1 Asia-Pacific Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Region (2021-2032)
- 8.3.2 China Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 8.3.3 Japan Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 8.3.5 India Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 8.3.7 Australia Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
9 South America
- 9.1 South America Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Type (2021-2032)
- 9.2 South America Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Application (2021-2032)
- 9.3 South America Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Country
- 9.3.1 South America Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
10 Middle East & Africa
- 10.1 Middle East & Africa Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa Killer-cell immunoglobulin-like receptors (KIRs) Market Size by Country
- 10.3.1 Middle East & Africa Killer-cell immunoglobulin-like receptors (KIRs) Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
- 10.3.4 UAE Killer-cell immunoglobulin-like receptors (KIRs) Market Size and Forecast (2021-2032)
11 Market Dynamics
- 11.1 Killer-cell immunoglobulin-like receptors (KIRs) Market Drivers
- 11.2 Killer-cell immunoglobulin-like receptors (KIRs) Market Restraints
- 11.3 Killer-cell immunoglobulin-like receptors (KIRs) Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Killer-cell immunoglobulin-like receptors (KIRs) Industry Chain
- 12.2 Killer-cell immunoglobulin-like receptors (KIRs) Upstream Analysis
- 12.3 Killer-cell immunoglobulin-like receptors (KIRs) Midstream Analysis
- 12.4 Killer-cell immunoglobulin-like receptors (KIRs) Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Killer-cell immunoglobulin-like receptors (KIRs). Industry analysis & Market Report on Killer-cell immunoglobulin-like receptors (KIRs) is a syndicated market report, published as Global Killer-cell immunoglobulin-like receptors (KIRs) Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Killer-cell immunoglobulin-like receptors (KIRs) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
